The Shotlee Journal
Browse Shotlee articles about Metabolic Health.
Showing 9 / 744 Metabolic Health articles
Novo Nordisk's stock has erased the last of its Wegovy-driven gains in a brutal week, down 21% after next-gen obesity drug CagriSema underperformed rivals. Despite 20.2% weight loss in trials, analysts downgrade amid patent cliffs and competition from Eli Lilly's tirzepatide. The company's pivot to oral Wegovy offers hope, but diversification pressures mount.
The UK's MHRA has issued a critical warning about counterfeit Mounjaro pens following reports from Eli Lilly. These fake pens contain tirzepatide but may not be sterile, posing potential health risks. Patients are urged to verify batch numbers and report suspicions to the Yellow Card scheme.
Just as smartphones propelled Ireland's economy post-financial crisis, GLP-1 weight-loss drugs like Eli Lilly's Mounjaro and Zepbound are set to do the same. With factories in Kinsale and Limerick producing key ingredients, Ireland eyes massive tax windfalls and export spikes. Gallup data shows US obesity falling to 37%, crediting these therapies.
As the Ozempic generation ramps up protein intake to support weight loss, Minneapolis-based Puris Proteins has surged to $200 million in revenue as America's top pea protein maker. From basement soybean breeding to supplying giants like Cargill, this family business is powering nutritious habits for GLP-1 users. Here's the story behind their explosive growth.
Eli Lilly's investigational GLP-1 pill, orforglipron, demonstrated greater weight loss and blood sugar control than oral semaglutide in a major phase 3 trial for type 2 diabetes. Patients lost 6-8% body weight compared to 4-5%, though with higher GI side effects. This could signal a shift toward more effective oral therapies.
With federal Obamacare subsidies expired, premiums have surged, but ten states are stepping in with their own aid to keep coverage affordable. New Mexico fully replaces the gap for all incomes, while others target low earners amid cost pressures from GLP-1 drugs like Ozempic and Wegovy. Enrollment trends vary, with some states seeing gains despite national drops.
New research reveals that pairing GLP-1 receptor agonists with healthy lifestyle habits significantly lowers heart attack, stroke, and CV death risk in type 2 diabetes patients. Those following 6-8 habits plus GLP-1 therapy saw a 43% reduced MACE risk. This study highlights their complementary roles in heart health.
GLP-1 medications are reshaping bakery demands, driving growth in high-fiber, high-protein products. Ardent Mills is leading with benefit-stacking strategies using UltraGrain flour and chickpea ingredients to support satiety and digestive health for users. This guide details the research, innovations, and future outlook.
As GLP-1 medications surge in popularity, the Institute of Food Technologists (IFT) is guiding brands on functional foods to fill nutrition gaps. From Danone’s Oikos Fusion yogurt to fiber-woven snacks by Lasso, discover how proteins, prebiotics, and micronutrients support satiety and muscle health for users.
